$CVM CEL-SCI Reports Fiscal First Quarter 2026 Results
Set to Commence Patient Enrollment Summer of 2026 in Pivotal U.S. FDA Head and Neck Cancer Registration Study
Entering Saudi Oncology Market, Potentially Through Key Partnerships to Advance Multikine Approval and Commercialization
https://www.businesswire.com/news/home/202602...-Results
Set to Commence Patient Enrollment Summer of 2026 in Pivotal U.S. FDA Head and Neck Cancer Registration Study
Entering Saudi Oncology Market, Potentially Through Key Partnerships to Advance Multikine Approval and Commercialization
https://www.businesswire.com/news/home/202602...-Results